The DOI matches its Crossref record.
Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome
Abstract
PURPOSE: We evaluated the efficacy, tolerability and safety of the new antimuscarinic agent fesoterodine relative to placebo for overactive bladder syndrome. MATERIALS AND METHODS: This was a randomized, double-blind, placebo controlled, multicenter trial performed in the United States. Overall 836 subjects with urinary frequency, urinary urgency or urgency urinary incontinence were randomized to placebo (274), 4 mg fesoterodine (283) or 8 mg fesoterodine (279) once daily for 12 weeks. The primary efficacy end point was the change in the number of micturitions per 24 hours. Co-primary end points were the change in the number of urgency urinary incontinence episodes per 24 hours and the treatment response. Secondary efficacy end points were other bladder diary variables, such as the change in mean voided volume per micturition, number of continent days and number of urgency episodes per 24 hours. Tolerability and safety were assessed by evaluating adverse events, electrocardiograms, post-void residual urine volume, laboratory parameters and treatment withdrawals. RESULTS: Treatment with 4 or 8 mg fesoterodine resulted in statistically significant and clinically relevant improvements from baseline to end of treatment for the primary and co-primary end points compared with placebo (p <0.05). Results for most secondary end points, including mean voided volume per micturition, number of continent days and number of urgency episodes per 24 hours, were also significantly improved vs placebo. The adverse events reported more frequently with fesoterodine than with placebo were dry mouth, constipation and urinary tract infection. CONCLUSIONS: The 2 doses of fesoterodine were well tolerated and they statistically significantly improved overactive bladder symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chapple, C. R., Khullar, V., Gabriel, Z., Muston, D., Bitoun, C. E., & Weinstein, D. (2008) · European Urology · doi:10.1016/j.eururo.2008.06.047 · Cited by 769
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.09.079 · Cited by 710
Osman, N. I., Chapple, C. R., Abrams, P., Dmochowski, R., Haab, F., Nitti, V., Koelbl, H., van Kerrebroeck, P., & Wein, A. J. (2014) · European Urology · doi:10.1016/j.eururo.2013.10.015 · Cited by 380
Self-citationNovara, G., Galfano, A., Secco, S., D'Elia, C., Cavalleri, S., Ficarra, V., & Artibani, W. (2008) · European Urology · doi:10.1016/j.eururo.2008.06.080 · Cited by 269
Maman, K., Aballea, S., Nazir, J., Desroziers, K., Neine, M.-E., Siddiqui, E., Odeyemi, I., & Hakimi, Z. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.010 · Cited by 259
Metadata
- Authors
- Nitti, V. W., Dmochowski, R., Sand, P. K., Forst, H.-T., Haag-Molkenteller, C., Massow, U., Wang, J., Brodsky, M., & Bavendam, T.
- Venue
- Journal of Urology
- Published
- 2007-12
- Volume
- 178
- Issue
- 6
- Pages
- 2488-2494
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2064365016
- Cited by
- 187
- References
- 0
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome. https://app.cochat.ai/papers/10.1016/j.juro.2007.08.033
- The paper
- Nitti, V. W., Dmochowski, R., Sand, P. K., Forst, H.-T., Haag-Molkenteller, C., Massow, U., Wang, J., Brodsky, M., & Bavendam, T. (2007). Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome. Journal of Urology. https://doi.org/10.1016/j.juro.2007.08.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.